Results 221 to 230 of about 11,213,687 (295)

Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial. [PDF]

Signal Transduct Target Ther
Ji L, Gao L, Li B, Liu M, Zhang X, Meng C.   +5 more
europepmc   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Efficacy and Safety of Intraventricular Thiotepa in Combination With Methotrexate for Leptomeningeal Metastasis From Breast Cancer (NJMU-BC04): A Single-Arm Phase II Study. [PDF]

MedComm (2020)
Zhou W, Zha M, Fang H, Cao K, Yong J, Sun Y, Yuan Y, Zhang J, Fang S, Ding Q, Li W.   +10 more
europepmc   +1 more source

Somatostatin receptor 4 (SSTR4) is a tumor suppressor in cutaneous and head & neck squamous cell carcinomas

Molecular Oncology, EarlyView.
This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi, Tuan Khang Huynh, Adway Kadam, Zahra Kardan, Yue Yan, Amina Jamal Laham, Sampath Kumar Loganathan   +6 more
wiley   +1 more source

FocaSaBra: a prospective phase II study on focal salvage brachytherapy for prostate cancer recurrence after radiotherapy - trial design. [PDF]

Rep Pract Oncol Radiother
Burchardt WM, Kluska A, Chicheł A, Zwierzchowski G, Burchardt E, Bielęda G, Chyrek AJ.   +6 more
europepmc   +1 more source

ADP‐ribosylation: An emerging regulator of the epigenome

Molecular Oncology, EarlyView.
ADP‐ribosylation has emerged as a dynamic epigenetic signaling mechanism that modifies histones and chromatin‐associated proteins. Through coordinated PARylation and MARylation, it integrates with other histone modifications to regulate chromatin structure, transcription factor activity, and gene expression, influencing genome function and disease ...
Cristel V. Camacho, Chenqian Liu, W. Lee Kraus   +2 more
wiley   +1 more source

phase II study

OTOLOGIA FUKUOKA, 1980
openaire   +1 more source

Correction: Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial. [PDF]

Bone Marrow Transplant
Van Dijck R, van der Holt B, Broers AEC, Hazenberg MD, Devos T, van der Poel MWM, Breems D, Deleu L, Schuthof BAG, van Hooije CMC, Cornelissen JJ, Schaap NPM, Te Boekhorst PAW.   +12 more
europepmc   +1 more source